Patents matching “pd-”

US 10221244

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

US 10167334

Treatment of cancer using anti-TGF-BETA and PD-1 antibodies

The Regents of the University of California · Granted Jan 1, 2019 · Expires Dec 27, 2038

US 10010587

IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

Nektar Therapeutics · Granted Jul 3, 2018 · Expires Jun 28, 2038

US 9987500

Human antibodies to PD-1

REGENERON PHARMACEUTICALS, INC. · Granted Jun 5, 2018 · Expires May 31, 2038

US 9938345

Human antibodies to PD-L1

REGENERON PHARMACEUTICALS, INC. · Granted Apr 10, 2018 · Expires Apr 5, 2038

US 9932593

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. · Granted Apr 3, 2018 · Expires Mar 29, 2038

US 9765147

Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

US 9422562

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. · Granted Aug 23, 2016 · Expires Aug 18, 2036

US 8507663

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. · Granted Aug 13, 2013 · Expires Aug 8, 2033